APA (7th ed.) Citation

X, L., HC, L., JA, Z., M, M., K, R., C, H., . . . E, T. (2024). INSURE: A pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice. Future oncology (London, England), 20(14), 935. https://doi.org/10.2217/fon-2023-0604

Chicago Style (17th ed.) Citation

X, Leleu, et al. "INSURE: A Pooled Analysis of Ixazomib-lenalidomide-dexamethasone for Relapsed/refractory Myeloma in Routine Practice." Future Oncology (London, England) 20, no. 14 (2024): 935. https://doi.org/10.2217/fon-2023-0604.

MLA (9th ed.) Citation

X, Leleu, et al. "INSURE: A Pooled Analysis of Ixazomib-lenalidomide-dexamethasone for Relapsed/refractory Myeloma in Routine Practice." Future Oncology (London, England), vol. 20, no. 14, 2024, p. 935, https://doi.org/10.2217/fon-2023-0604.